down arrow

Galmed Pharmaceuticals Ltd.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: IL0011313900
USD
1.13
0.17 (17.84%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

1.031.15

52 Week

0.743.61
Valuation
Technical
Day's Volume

CASH

346.05 k

Shareholding (Mar 2025)

FII

0.00%

Held by 3 FIIs

DII

100.0%

Held by 0 DIIs

Promoter

0.00%

How big is Galmed Pharmaceuticals Ltd.?

22-Jun-2025

As of Jun 18, Galmed Pharmaceuticals Ltd. has a market capitalization of 3.78 million and reported net sales of 0.00 million with a net profit of -7.34 million. Shareholder's funds are 16.33 million, and total assets are 18.50 million.

As of Jun 18, Galmed Pharmaceuticals Ltd. has a market capitalization of 3.78 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the company reported net sales of 0.00 million for the latest four quarters. During the same period, the consolidated net profit was -7.34 million.<BR><BR>As of Dec 24, the balance sheet shows shareholder's funds of 16.33 million and total assets of 18.50 million.

Read More

What does Galmed Pharmaceuticals Ltd. do?

22-Jun-2025

Galmed Pharmaceuticals Ltd. is an Israeli biopharmaceutical company focused on developing therapies for liver diseases, particularly Non-alcoholic Steatohepatitis (NASH), with its main product being Arachmol. As of March 2025, it has a market cap of USD 3.78 million and reported a net profit of -1 million.

Overview:<BR>Galmed Pharmaceuticals Ltd. is an Israeli-based clinical-stage biopharmaceutical company focused on developing therapies for treating liver diseases, specifically targeting Non-alcoholic Steatohepatitis (NASH) with its main product, Arachmol.<BR><BR>Financial Snapshot:<BR>Most recent Net Profit: -1 Million (Quarterly Results - Mar 2025)<BR>Market-cap: USD 3.78 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making)<BR>Industry P/E: NA<BR>Dividend Yield: 0.00%<BR>Debt Equity: -0.94<BR>Return on Equity: -36.74%<BR>Price to Book: 0.22<BR><BR>Contact Details:<BR>Address: 16 Ze'ev Tyomkin St. (4Th Fl.), TEL AVIV-YAFO None: 6578317<BR>Tel: 972 3 6938448<BR>Fax: 972 3 6938447<BR>Website: http://www.galmedpharma.com

Read More

Who are in the management team of Galmed Pharmaceuticals Ltd.?

22-Jun-2025

As of March 2022, the management team of Galmed Pharmaceuticals Ltd. includes President and CEO Allen Baharaff, Lead Independent Director Dr. David Sidransky, Directors Marshall Heinberg and Prof. Ran Oren, and Independent Directors Dr. Carol Brosgart and William Marth. They oversee the company's strategic direction and operations.

As of March 2022, the management team of Galmed Pharmaceuticals Ltd. includes the following individuals:<BR><BR>- Mr. Allen Baharaff, who serves as the President, Chief Executive Officer, and Director.<BR>- Dr. David Sidransky, who is the Lead Independent Director.<BR>- Mr. Marshall Heinberg, who is a Director.<BR>- Prof. Ran Oren, who is also a Director.<BR>- Dr. Carol Brosgart, who serves as an Independent Director.<BR>- Mr. William Marth, who is another Independent Director. <BR><BR>This team is responsible for guiding the strategic direction and operations of the company.

Read More

Is Galmed Pharmaceuticals Ltd. overvalued or undervalued?

25-Jun-2025

As of November 6, 2019, Galmed Pharmaceuticals Ltd. is considered overvalued with a valuation grade of "does not qualify," reflected by a Price to Book Value of 0.20, an EV to EBITDA of 2.05, a negative ROE of -36.74%, and a year-to-date stock performance of -45.14% compared to the S&P 500's 2.44%.

As of 6 November 2019, the valuation grade for Galmed Pharmaceuticals Ltd. moved from risky to does not qualify. The company is considered overvalued given its financial metrics, particularly with a Price to Book Value of 0.20 and an EV to EBITDA of 2.05, despite being a loss-making entity. The Return on Equity (ROE) stands at a concerning -36.74%, indicating significant inefficiencies in generating profits from equity.<BR><BR>In comparison to its peers, Galmed Pharmaceuticals Ltd. shows a less favorable position, with Avalo Therapeutics, Inc. having an EV to EBITDA of 1.48 and ABVC BioPharma, Inc. showing a much lower valuation with an EV to EBITDA of -21.96. The recent stock performance reflects a stark contrast to the S&P 500, with a year-to-date return of -45.14% compared to the index's 2.44%, reinforcing the notion that the company is overvalued in its current state.

Read More

Is Galmed Pharmaceuticals Ltd. technically bullish or bearish?

20-Sep-2025

As of September 12, 2025, Galmed Pharmaceuticals Ltd. is in a bearish trend with weak strength, indicated by negative signals from moving averages and KST, despite some mildly bullish MACD signals, and has significantly underperformed the S&P 500 with a year-to-date return of -52.66%.

As of 12 September 2025, the technical trend for Galmed Pharmaceuticals Ltd. has changed from mildly bearish to bearish. The current stance is bearish with weak strength, driven by bearish signals from the daily moving averages and the KST on both weekly and monthly time frames. The MACD shows mildly bullish signals on weekly and monthly charts, but this is overshadowed by the overall bearish indicators. Additionally, the stock has significantly underperformed against the S&P 500 across multiple periods, with a year-to-date return of -52.66% compared to the S&P 500's 12.22%, and a one-year return of -78.12% versus 17.14% for the benchmark.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 8 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-1.01

stock-summary
Return on Equity

-34.36%

stock-summary
Price to Book

0.37

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-2 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-12.4%
0%
-12.4%
6 Months
-23.65%
0%
-23.65%
1 Year
-60.63%
0%
-60.63%
2 Years
-74.31%
0%
-74.31%
3 Years
269.52%
0%
269.52%
4 Years
-99.72%
0%
-99.72%
5 Years
-99.84%
0%
-99.84%

Galmed Pharmaceuticals Ltd. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is Galmed Pharmaceuticals Ltd. technically bullish or bearish?

As of 12 September 2025, the technical trend for Galmed Pharmaceuticals Ltd. has changed from mildly bearish to bearish. The current stance is bearish with weak strength, driven by bearish signals from the daily moving averages and the KST on both weekly and monthly time frames. The MACD shows mildly bullish signals on weekly and monthly charts, but this is overshadowed by the overall bearish indicators. Additionally, the stock has significantly underperformed against the S&P 500 across multiple periods, with a year-to-date return of -52.66% compared to the S&P 500's 12.22%, and a one-year return of -78.12% versus 17.14% for the benchmark....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
11.57%
EBIT to Interest (avg)
-20.55
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.94
Sales to Capital Employed (avg)
0
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
6.72%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.20
EV to EBIT
2.03
EV to EBITDA
2.05
EV to Capital Employed
-12.13
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-36.74%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
Bullish
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
No Trend
Mildly Bearish
OBV
No Trend
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Foreign Institutions

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 3 Foreign Institutions (0.0%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -127.27% vs 31.25% in Jun 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-2.10",
          "val2": "-1.10",
          "chgp": "-90.91%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.50",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-2.50",
          "val2": "-1.10",
          "chgp": "-127.27%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -8.70% vs 61.45% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-6.20",
          "val2": "-7.50",
          "chgp": "17.33%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-1.10",
          "val2": "0.30",
          "chgp": "-466.67%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-7.50",
          "val2": "-6.90",
          "chgp": "-8.70%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-2.10
-1.10
-90.91%
Interest
0.00
0.00
Exceptional Items
-0.50
0.00
Consolidate Net Profit
-2.50
-1.10
-127.27%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is -127.27% vs 31.25% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-6.20
-7.50
17.33%
Interest
0.00
0.00
Exceptional Items
-1.10
0.30
-466.67%
Consolidate Net Profit
-7.50
-6.90
-8.70%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -8.70% vs 61.45% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Galmed Pharmaceuticals Ltd. stock-summary
stock-summary
Galmed Pharmaceuticals Ltd.
Pharmaceuticals & Biotechnology
Galmed Pharmaceuticals is a Israeli-based clinical-stage biopharmaceutical company.The activiti of the Company is focused on the development therapy for treating liver diseases. Arachmol, the main product of Galmed Pharmaceuticals, is a liver-targeted stearoyl-coenzyme A desaturase1 used in oral therapy for the treatment of NASH (Non-alcoholic Steatohepatitis).
Company Coordinates stock-summary
Company Details
16 Ze'ev Tyomkin St. (4Th Fl.) , TEL AVIV-YAFO None : 6578317
stock-summary
Tel: 972 3 6938448
stock-summary
http://www.galmedpharma.com
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."